Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
about
Molecular Mechanisms and Metabolomics of Natural Polyphenols Interfering with Breast Cancer MetastasisPersonalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer.Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based studyOverexpression of NSUN2 by DNA hypomethylation is associated with metastatic progression in human breast cancer.Current breast cancer proliferative markers correlate variably based on decoupled duration of cell cycle phases.Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IXAnalytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study.The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypesIs Chemoendocrine Treatment without Alternative?Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.Pulmonary Adenocarcinoma in Malignant Pleural Effusion Enriches Cancer Stem Cell Properties during Metastatic CascadeRole of activated Rac1/Cdc42 in mediating endothelial cell proliferation and tumor angiogenesis in breast cancer.Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodiesStrategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 studyAssessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working groupClinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trialKi-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewRelative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.Prognostic Significance of Transverse Relaxation Rate (R2*) in Blood Oxygenation Level-Dependent Magnetic Resonance Imaging in Patients with Invasive Breast Cancer.Poorer Prognosis of Primary Signet-Ring Cell Carcinoma of the Breast Compared with Mucinous Carcinoma.Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma.Biomarkers in Breast Cancer - An UpdatePrognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancerA risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancerThe 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registryLateral differences in Ki-67 in breast cancerBreast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response.
P2860
Q28076953-C8AE1188-B600-4E7E-821A-BFA9FA1CDAC0Q30543788-483E03FE-8C43-4138-A4A6-21CB83D66848Q33484404-03801A03-BCC1-4E6D-B7E6-0588DB543AA1Q33584351-BCBCF14D-A5C5-41F3-BE15-E31726BDCB2EQ33591335-ADC10838-4B03-4FDA-B55D-D62F7938673CQ33687123-14D072F1-B285-44B5-9A67-D460432D4B41Q33692020-8AD908BE-A41F-46E7-ACCF-FB18B0CA7C3DQ33698446-23A59E01-D4CC-4F5F-B644-999464EFF24FQ33739357-AD92276C-7D65-4CE0-8E23-05FB633199DDQ33915010-1DF30EB0-AD08-4682-8F67-941D4915F599Q34109691-78F3D28A-4511-4C38-8299-BDCE275B55FEQ34171441-D72AE93C-9D84-4BAC-BDAE-FD3215710856Q34284263-A1EE68A9-9559-452E-AAA8-12B370BFB114Q34315684-AC706695-3779-4F63-BC49-9D30B4DF9337Q34712278-311A6FE8-EE39-41D5-80AD-E9DF8B0EA1A7Q34764393-069055C0-DB3D-4F35-9A02-D5CD09F29150Q34775344-CA3F87C5-93C5-437F-AAE1-7A91F14ADE86Q35130819-69A25ED9-037D-4937-9916-E2E485DE277EQ35230269-5C5DB2D9-B434-443D-A6B8-C6FB15BE49FDQ35450768-64A057EB-5D29-401F-AC16-18DA77BBAFDFQ35462377-59DDCD8E-CDE2-4B36-9A1D-2665FEB7B412Q35552069-3D2D8467-D911-48A6-B726-26AEDD287CFCQ35566057-A2F7935E-980F-4F92-9801-A7411092605AQ35620685-3810BC4E-BD13-49AC-AF7D-B61FE214E9EBQ35889568-A82326C3-9236-4C51-BD5E-434F32DB890DQ35904441-07970E5C-0A93-4515-A98F-38B8FF92BB31Q35998828-83FA0112-DB9B-478F-ACEA-16C9A7557C32Q36069162-9371688F-517E-4688-9C14-EB6F6E480D0AQ36119807-177C6321-45DD-43AB-9E3A-552DE621C1A7Q36295045-1D055EE5-1F48-441E-8601-2853FC1BDD8BQ36295142-3B7F73C3-4B71-45C7-B73A-29F32AD92D4CQ36393082-FAA476F4-6BE6-4AA1-92D1-541B219866D3Q36593931-179D172A-1574-48C6-A9CB-A0DA7057CA8CQ36615770-BDA7E64C-2C98-4655-A726-ADB5EFA2C240Q36653693-05F77704-64D1-495E-B7AB-BB3401CE9AFDQ36658463-BBB4649A-BEF6-4F0F-B949-3454D61E29A0Q36732425-9B8A414A-E404-4290-B371-C1F09DC4D94DQ36892788-9F7D0858-3DF8-481C-8604-E3CD3E21C2D1Q36953869-BCF278C2-3448-461B-881B-3CD171373710Q36997754-D0D47AC6-0E57-4556-9298-49E50EB3309A
P2860
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Predictive value of tumor Ki-6 ...... r node-negative breast cancer.
@en
Predictive value of tumor Ki-6 ...... r node-negative breast cancer.
@nl
type
label
Predictive value of tumor Ki-6 ...... r node-negative breast cancer.
@en
Predictive value of tumor Ki-6 ...... r node-negative breast cancer.
@nl
prefLabel
Predictive value of tumor Ki-6 ...... r node-negative breast cancer.
@en
Predictive value of tumor Ki-6 ...... r node-negative breast cancer.
@nl
P2093
P2860
P50
P356
P1476
Predictive value of tumor Ki-6 ...... or node-negative breast cancer
@en
P2093
Alan S Coates
Anikó Kovács
Aron Goldhirsch
Barry A Gusterson
Christian Ohlschlegel
Fausto Maffini
International Breast Cancer Study Group
Karen N Price
Komala Pillay
Meredith M Regan
P2860
P304
P356
10.1093/JNCI/DJM289
P407
P577
2008-01-29T00:00:00Z